Skip to main navigation
Skip to content
InMed-logo-01

    Pharmaceutical Programs

  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Rare Cannabinoid Manufacturing

  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ - Cannabinoid Manufacturing
    • Baymedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • IR Nav

  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About

  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn

  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu

    Pharmaceutical Programs

  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Rare Cannabinoid Manufacturing

  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ - Cannabinoid Manufacturing
    • Baymedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • IR Nav

  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About

  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn

  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Subscribe
NASDAQ_Logo

SEC Filing

SEC Filing Details

Document Details

Form
4
Filing Date
Dec 19, 2022
Document Date
Dec 16, 2022
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
InMed Pharmaceuticals Inc.
Issuer
InMed Pharmaceuticals Inc.
Filer
ADAMS ERIC A

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical Programs

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

Rare Cannabinoid Manufacturing

Manufacturing

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ - Cannabinoid Manufacturing
  • Baymedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

IR Nav

Investor

  • News Releases
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

About

Corporate

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabis Treatments for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Legal Nav

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer

Social icons

  • Find Us On:
  • >
  • >
  • >